BBOT · BridgeBio Oncology Therapeutics Inc.

Summary

On March 24, 2026, BridgeBio Oncology Therapeutics, Inc. increased its Board size to nine directors and appointed Peter Lebowitz, M.D., Ph.D. as a Class I director, effective immediately, to serve on the NCG Committee and Compensation Committee. Dr. Lebowitz, determined to be independent, received a one-time nonqualified stock option to purchase 63,350 shares at $8.72 per share.

Key takeaways

• Board size increased to nine directors on March 24, 2026
• Peter Lebowitz, M.D., Ph.D. appointed as Class I director, term expires at 2026 annual meeting
• Dr. Lebowitz appointed to NCG Committee and Compensation Committee
• Board determined Dr. Lebowitz is independent per Nasdaq rules
• Automatic grant of stock option for 63,350 shares at $8.72 exercise price, closing price on March 24, 2026
• Compensation per amended non-employee director policy filed in 10-K on March 5, 2026